Clinical Trials Logo

Filter by:
NCT ID: NCT04434105 Active, not recruiting - Clinical trials for Carpal Tunnel Syndrome

Ultrasound-guided PRP Versus Steroid Injections in Management of Carpal Tunnel Syndrome

Start date: February 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Patients will be randomly divided into 3 equal groups: Group I received ultrasound guided injection of 2 mL PRP into the affected carpal tunnel. Group II received ultrasound guided injection of 2 mL steroids (40 mg triamcinolone acetonide). Group III received ultrasound guided injection of 2 mL saline as placebo control.

NCT ID: NCT04431882 Active, not recruiting - Clinical trials for Optic Nerve Sheath Fenestration

The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure

Start date: June 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Optic nerve sheath fenestration (ONSF) first described by De Wecker in 1872 for the treatment of neuroretinitis. Since then, optic nerve sheath fenestration has become well established procedure for treatment of papilledema in medically uncontrolled patients of idiopathic intracranial hypertension.

NCT ID: NCT04425161 Active, not recruiting - Septic Shock Clinical Trials

Ratio of ''Central Venous-to-Arterial Co2 Gap'' to ''Arterial-to-Central Venous O2 Content Gap'' in Septic Shock

Start date: July 20, 2020
Phase:
Study type: Observational

The high ratio of "central venous to arterial carbon dioxide" to "arterial to central venous oxygen content " is associated with elevated lactate in patients with septic shock. So, the aim of the present study is to evaluate the ratio of "central venous-to-arterial CO2 tension or content" to "arterial-to-venous O2 content'' as an indicator of anaerobic metabolism in septic shock.

NCT ID: NCT04422522 Active, not recruiting - Clinical trials for Fibromyalgia, Primary

Fibromyalgia During the COVID-19 Pandemic

Start date: March 15, 2020
Phase:
Study type: Observational

On 12 January 2020, the World Health Organization (WHO) confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan City, Hubei Province, China, which was reported to the WHO on 31 December 2019. There is evidence of a high prevalence of psychiatric comorbidities in Fibromyalgia (FM )(especially depression, anxiety, post-traumatic stress disorder), which are associated with a worse clinical profile. In these challenging times of COVID-19, anxiety increased among the general population. Fibromyalgia patients are more at risk of developing anxiety in these difficult times. This might result in more frequent visits to the rheumatology clinics with an exacerbation of their chronic pain syndrome.

NCT ID: NCT04416113 Active, not recruiting - Clinical trials for Photodynamic Therapy& Low Level Laser in Management of COVID 19

Photodynamic Therapy for the Treatment of COVID-19

Start date: August 5, 2021
Phase: N/A
Study type: Interventional

Until now there is no vaccine or reliable treatment for the COVID-19 pandemic. The fundamental mechanisms of non-invasive low-level laser in photobiomodulation (PBM) and photodynamic therapy is to stimulate the mitochondrial respiratory chain where a transient release of non-cytotoxic levels of reactive oxygen species (ROS) will lead to positive modulation of the immune response. As previous studies mentioned that the most important strategy for COVID-19 management is oxygenation and faster rehabilitation of the damaged tissue, antiviral effects, and, finally, reduction or controlling the cytokine storm by reducing inflammatory agents. PBM may be used as adjuvant therapy or even an alternative therapy in all these mechanisms without side effects and drug interactions. Objectives The objective of this clinical trial is to use the photobiomodulation therapy (PBMT), and photodynamic therapy as adjuvant therapy or even an alternative therapy for Covide-19. Patients and methods A randomized controlled study will be conducted on 60 patients of positive COVID 19. The patients will be divided into 3 equal groups. Group, I will receive a low-level laser (diode laser 980nm) from laser watch for 30 minutes, 20 J for 3 to 5 days, and laser acupuncture. Group 2 will be treated with photodynamic therapy by injecting the methylene blue as a photosensitizer and irradiated with laser watch (diode laser 670 nm). Group 3 will serve as a control. Evaluation methods will include laboratory investigations and CT chest.

NCT ID: NCT04410341 Active, not recruiting - Clinical trials for Major Depressive Disorder

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

Start date: May 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (DPP-4), increases glucagon-like peptide-1 (GLP-1) and regulates blood glucose levels, favoring weight loss and lowering cardiovascular risk. A retrospective longitudinal study by Rizzo et al. showed that DPP-4 inhibitors administration could have protective effects against cognitive decline in diabetic elderly. Is has been observed that GLP-1 affects brain metabolism, increases neuritic growth, and protects neuronal cells from oxidative stress and death.

NCT ID: NCT04393064 Active, not recruiting - Clinical trials for Fiberoptic Endoscope Evaluation of Swallowing in Infants(FEES)

Fiberoptic Endoscopic Evaluation of Swallowing(FEES) in Infants Graduated From (NICU) Neonatal Intensive Care Unite

FEES
Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Based on study showing the ability of using FEES in infant in NICU; so the aim of this study to screen the newborns graduated from NICU using clinical bed side evaluation as well as flexible endoscopic assessment of swallowing to identify the ones suffering from oropharyngeal and / or esophageal dysphagia as well as newborns at risk for aspiration &aspiration pneumonia to tailor or identify appropriate feeding plan for those high risk popularities and support them

NCT ID: NCT04389619 Active, not recruiting - Hypertrophic Scars Clinical Trials

Fractional Microneedling RF vs Intralesional Steroid With & Without Microneedling in Hypertrophic Scars

Start date: May 10, 2020
Phase: N/A
Study type: Interventional

Comparing between the effect of Fractional Microneedling Radiofrequency Versus Intralesional Steroid Injection with and without Microneedling on Tissue levels of PDGF & CTGF in Hypertrophic Scars

NCT ID: NCT04388436 Active, not recruiting - COVID Clinical Trials

Post Covid-19 Cardiopulmonary and Immunological Changes

covid-19
Start date: May 11, 2020
Phase:
Study type: Observational [Patient Registry]

Study rationale and aim: Resolving the COVID-19 pandemic quickly hinges on a crucial factor: how well a person's immune system remembers SARS-CoV-2, the virus behind the disease, after an infection has resolved and the patient is back in good health. This phenomenon, called immune memory, helps our bodies avoid reinfection by a bug persons have had before and influences the potency of life-saving treatments and vaccines. Also, the new coronavirus causes cardiac and pulmonary inflammation. So, our study planned to measure the cardiopulmonary and immunological changes in treated COVID-19 patients. Specific objectives: Measurement the duration of existence of COVID-19 IgM and IgG antibody in patient's plasma, detection of cardiac changes, pulmonary radiological and functional changes after COVID-19 infection. This could help detection of functional impairment in COVID-19 survivors which may have economic and social impact. Also, investigator will assess possible protective immune response following infection which may affect vaccination schedule. Methods: One hundred RT- PCR positive COVID-19 patients will be enrolled. HRCT chest, lateral flow immunoassay, spirometry, DLCO and Echo will be done on after 3, 6 and 12 months of discharge.

NCT ID: NCT04384250 Active, not recruiting - Clinical trials for Genetic Basis of COVID-19 Infection

Genetic and Immunologic Basis of COVID-19 Infection

Start date: June 1, 2020
Phase:
Study type: Observational

We will study genetic factors causing severe disease due to infection with SARS-COV-2 which may help to find targeted therapy